The prognosis for patients with high-grade cerebral glioma is poor. Most treatment failures are due to local recurrence of tumor, indicating that a more aggressive local therapy could be beneficial. Adjuvant treatments such as porphyrin-sensitized photodynamic therapy (PDT) or boron neutron capture therapy (BNCT) have the potential to control local recurrence. The selective tumor uptake of a boronated porphyrin was studied in CBA mice bearing an implanted intracerebral glioma. Biopsy samples of tumor, normal brain, and blood were analyzed by a fluorometric assay following intraperitoneal and intravenous administration of boronated protoporphyrin (BOPP). This compound was selectively localized to tumor at ratios as high as 400:1 relative to normal brain.
Confocal laser scanning microscopy of glioma cells in vitro and in vivo showed that BOPP was localized within mitochondria and excluded from the nucleus of these cells. This discrete subcellular localization was confirmed by density gradient ultracentrifugation after homogenization of mouse tumor biopsies. The selective discrete localization of these compounds within the tumor suggests that this compound may be used as a dual PDT/BNCT sensitizer.
Primary cerebral tumors are responsible for -2% of all cancer deaths, with =10,000 persons dying per annum in the United States (1) . The majority of these deaths are due to the high-grade gliomas-anaplastic astrocytoma and glioblastoma multiforme. At present there is no satisfactory treatment for these tumors. Surgery provides a definitive histological diagnosis and relief of symptoms of raised intracranial pressure. Radiotherapy and adjuvant chemotherapy are of limited value and most studies utilizing these treatments report median survival times of <1 year (1, 2) . Most treatment failures are due to local recurrence of the tumor, suggesting that more aggressive local therapy could be beneficial. Two adjuvant therapies with the potential to control local recurrence are photodynamic therapy (PDT) and boron neutron capture therapy (BNCT).
PDT relies on the selective uptake or retention of a photosensitizing chemical in the tumor relative to surrounding normal tissue, followed by treatment with light of the appropriate wavelength to activate the photosensitizer (3) . The photoactivation of this sensitizer results in generation of a cytotoxic chemical species, probably singlet excited state oxygen, which leads to selective tumor necrosis (3) . Photosensitizers that have been used in most clinical and experimental studies to date are hematoporphyrin derivative (HpD) and its enriched commercial preparation Photofrin II (3), both of which have been shown to selectively localize in glioblastoma multiforme (4, 5) . Reports of PDT in the treatment of animal (5-7) and human (5, (7) (8) (9) gliomas have been encouraging, although the use of a more tumor-selective photosensitizer than HpD or Photofrin II would be desirable.
Like PDT, BNCT is based on selective tumor localization of a sensitizing agent, a compound containing 10B atoms, followed by activation of the sensitizer. However, in contrast to PDT, the activating beam of thermal neutrons can reach deep-seated tumor sites. The high linear energy transfer particles produced in the reaction, 4He and 7Li, have mean free paths of9 and 5 ,um, respectively, and deposit substantial energies within approximately one cell diameter. The short range of these products results in severe dependency of the cells on boron microlocalization. For a typical cell, it is calculated that 90% less boron is needed if it is located intracellularly as opposed to extracellularly (10) . Thus, both PDT and BNCT are binary treatments, the individual components of which are nontumoricidal but when combined have tumoricidal potential. While previous studies have suggested that BNCT might be a useful treatment for cerebral tumors (11) , data obtained from patients and animals injected with a variety of boron-containing compounds indicate that these chemicals do not exhibit high tumor selectivity relative to surrounding normal brain (12, 13) . Porphyrins present a potential solution to the problems of sensitizer uptake encountered in the application of BNCT for cerebral glioma since they have a much higher tumor selectivity and retention (4) than Na2B12H11SH, the agent currently used, and have a high carrying capacity for boron (14, 15) . To that end, several boronated porphyrins have been synthesized and we report here on the pharmacokinetics of one of these compounds, known as BOPP, in mice bearing the C6 intracerebral glioma xenograft (16) . BOPP is a tetrakiscarborane carboxylate ester of 2,4-(a,4-dihydroxyethyl)deuteroporphyrin IX (14) . The four closo-carborane cages, bearing 10 boron atoms each, provide BOPP with a boron weight percentage of nearly 30o. The compound is highly water soluble and is stable to physiologic conditions (17 Proc. Natl. Acad. Sci. USA 89 (1992) (pH 7.3) was from Commonwealth Serum Laboratories (Parkville, Australia). Percoll was purchased from Pharmacia-LKB and stored at 40C. BOPP was synthesized as described (14) and dissolved in 0.9o NaCl at a concentration of 10 mg/ml. This stock solution was stored at 40C in the dark and was routinely used within 24 hr.
Cells. The C6 rat glioma cell line was obtained from the American Type Culture Collection and the cells were grown at 370C in monolayer culture in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), both obtained from Commonwealth Serum Laboratories. Cells were harvested during the logarithmic phase of growth.
Intracranial Implantation of C6 Glioma. The C6 glioma model was grown as a xenograft in adult CBA mice as described (16) .
Administration of BOPP. The boronated porphyrin BOPP was dissolved in 0.9o NaCl before either intraperitoneal (i.p.) or intravenous (i.v.) tail vein administration into CBA mice bearing the intracranial C6 glioma. To study the kinetics of uptake, mice were injected with BOPP solution at the appropriate time points such that all were sacrificed exactly 14 days postimplantation of the tumor cells. To study the dose dependence of uptake, mice were injected with the appropriate dose of BOPP 13 days postimplantation of the tumor cells and were sacrificed 24 hr later.
Measurement of BOPP Uptake. On sacrifice, triplicate biopsy samples of tumor, normal brain, and venous blood were taken from all mice. Typically, 40-80 mg of tissue and 100 ul of blood were sampled. The level of BOPP was determined by an adaptation of a published method (4). Briefly, samples of known wet weight (or 100-pA volume in the case of blood) were homogenized in 6 ml of a solution containing 50 mM Hepes (pH 7.4), 10 mM CTAB using an Ystral type X1020 homogenizer (H.D. Scientific, Bayswater, Australia). Triplicate 2-ml aliquots of the homogenate were removed, and each was mixed with 5 ml of a chloroform/ methanol mixture (1:1; vol/vol), thoroughly Vortex mixed, and centrifuged at room temperature for 5 min at 2000 x g in a bench centrifuge (Clements GS200; Selby-Anax, Nottinghill, Australia). The upper phase and a layer of cell debris at the interface between upper and lower phases were discarded, and the lower phase was retained. All extracted BOPP was present in the lower phase, with no detectable porphyrin in the upper phase. Similarly, no BOPP was detectable in the debris layer after reextraction. The chloroform-rich lower phase was then evaporated to dryness under a stream of N2 gas, and the resulting residue was suspended in 1 ml of the 50 mM Hepes, pH 7.4/10 mM CTAB solution.
The absorbance of the solution at 400 nm was then determined with a Beckman DU65 spectrophotometer (Beckman) relative to a control blank. Those samples with higher absorbance values were diluted with 50 mM Hepes, pH 7.4/10 mM CTAB such that their final absorbance was equal to 0.15 absorbance unit in a 10-mm path length cell. This dilution step overcame the problem of concentration-dependent quenching of the BOPP fluorescence emission by either the extracted porphyrin or hemoglobin that was coextracted with BOPP from the tissue samples. A standard curve of BOPP coextracted in the presence ofadded hemolyzate showed that hemoglobin neither enhanced nor quenched the fluorescence, provided the absorbance measured at 400 nm in a 10-mm light path was below this limiting value of 0.15 absorbance unit.
Fluorescence of the samples was determined with a Perkin Elmer LS-30 spectrofluorimeter with the emission and excitation wavelengths set at 400 and 625 nm, respectively. 10 mM Hepes (pH 7.4) and the various subcellular fractions were isolated by ultracentrifugation in a TL-100 ultracentrifuge using a TLA-100.3 rotor (Beckman) on Percoll (Pharmacia-LKB) gradients as described (18) . The level of BOPP in the subcellular fractions from tumor and normal brain was then determined by extraction as described above, and the total protein content in each fraction was determined by the method of Lowry et al. (19) . At all times during isolation of the subcellular fractions, care was taken to minimize light exposure, which could cause photobleaching of the BOPP. RESULTS The selective uptake of BOPP into the intracerebral C6 xenograft is shown in Fig. 1 Fig. 2A ) or high (100 mg per kg of body weight; Fig. 2B ) doses. However, the uptake kinetics into blood were dependent on the route of administration. Maximum levels were detected 2 hr after i.v. injec- (Lower) A section adjacent to that shown in Upper stained with hematoxylin/eosin as described (16) to show the discrete intracerebral tumor. The operative procedure of tumor implantation and sacrifice of the animals was as described (16, 20) and was in accordance with approved guidelines of the Royal Melbourne Hospital Animal Ethics Committee. tion for both low and high doses, whereas for i.p. injection maximum levels were noted 24 and 18 hr after administration for the low and high doses, respectively. The rates of clearance from blood were also dependent on the route of administration, with much more rapid clearance after i.v. injection. Tumor levels remained relatively high throughout the experimental time course following high dose injection by either route, indicating the retention of BOPP in the tumor, even though blood levels fell substantially. The tumor/ normal brain and tumor/blood ratios for the data in Figs. 2 and 3 are shown in Table 1 . It is clear that BOPP is a highly selective tumor sensitizer. Ratios as high as 400:1 in tumor compared to normal brain were obtained 48 hr after i.v. injection of 100 mg of BOPP per kg of body weight, while at the same time point the tumor/blood ratio is 11:1.
The dose dependence of BOPP uptake 24 hr after administration is shown in Fig. 3 and the ratios derived from these data are shown in Table 1 . At doses >100 mg/kg, the tumor/brain and tumor/blood ratios decrease markedly, suggesting that the circulating blood plasma levels of BOPP are so high that its apparent selectivity is decreased. However, examination of these ratios at longer time points shows subsequent increases reflecting clearance of BOPP from plasma. Doses as high as 200 mg/kg were readily tolerated with no apparent signs of morbidity and no mortality of animals. The studies detailed above indicate the selectivity of uptake of BOPP into glioma but do not indicate the site(s) of localization within the gross tumor or the individual tumor cells. Confocal laser scanning microscopy (CLSM) was used to define the subcellular sites of BOPP localization in C6 cells grown in vitro and tumor in vivo. The micrographs (Fig. 4) show punctate fluorescence associated with discrete sites of localization in the perinuclear region and minimal uptake either into the nucleus or throughout the cytoplasm in vitro (Fig. 4A) Fig. 2 , except that a stock solution of BOPP (10 mg/ml in isotonic saline) was used. This was then diluted in isotonic saline such that each mouse was injected with the appropriate dose in a vol of 0.4 ml and sacrificed after 24 hr; tissue samples were then taken. Symbols and effors are as described in Fig. 2 . T/NB, tumor/normal brain; T/BL, tumor/blood. All values were calculated as the ratio of mean levels shown in Fig. 3. C6 glioma biopsies (Fig. 4B) , with BOPP detected intracellularly in the tumor bulk and in isolated nests of tumor cells infiltrating into the brain adjacent to tumor region. To define these sites of localization, C6 tumor tissue and normal brain from BOPP-sensitized mice (50 mg per kg of body weight) were homogenized and subcellular fractions were isolated by density gradient ultracentrifugation (18) . The results in Table  2 demonstrate that these discrete sites of fluorescence are within the mitochondria, with low levels in the cytoplasm, lysosomes, and Golgi. with tumor concentrations of 10B >20 pug/g, provided the concentration in the blood and parenchyma of the central nervous system is significantly lower (13) . The results presented in Fig. 2 show that 24 hr after administration of BOPP, the levels in the C6 glioma xenograft are higher than in blood and normal brain irrespective of whether the i.p. or i.v. route is used at both low or high doses. Since BOPP is 30%o boron by weight, then a BOPP concentration in tumor >65 pug/g would result in boron levels above this threshold of 20 pug/g. The data in Fig. 2B show that 24 hr after a dose of 100 mg of BOPP per kg of body weight, these levels are reached, with correspondingly low levels in blood and normal brain (Table  3) . However, even more importantly, the intracellular location of BOPP described in Fig. 4 has been calculated to result in a 10-fold reduction in the amount of boron required to achieve tumor necrosis, since there is more efficient targeting of critical subcellular structures (10) . Thus, the tumor levels reported in this study are well above this threshold even at the low BOPP dose of 10 mg per kg of body weight.
Previous studies using slow infusion of the sulfhydryl derivative of icosahedral borane, Na2B12HjjSH, in a patient with glioblastoma multiforme showed tumor concentrations of 2-6 ,ug of boron per g, with parenchymal concentrations of -1 ,ug/g (13) . However, Na2B12H11SH has not been shown to localize intracellularly in glioma cells, indicating that an alternative sensitizer is required, since these levels are below the clinically useful threshold value. In contrast, tumor boron levels of =12 ,ug/g and 63 ,ug/g using i.v. doses of 10 and 100 mg of BOPP per kg ofbody weight, respectively, are reported in this study. In addition, the selectivity of this uptake means that the levels in normal tissue and blood are very low, while the intracellular localization suggests it will be extremely dose effective. Interestingly, the maximal tumor levels were observed after 24 hr at either low or high dose, irrespective of the route of administration. This is in contrast to the kinetics of HpD uptake in the same animal model, where maximal tumor levels are observed 6 and 24 hr after administration for i.v. and i.p. routes, respectively (20) . The nature of the HpD mixture, which is composed of both hydrophobic and hydrophilic components (3), is probably the basis for these differences in uptake kinetics. The fluorescence assay used to determine HpD uptake measures total porphyrin content in the tumor (4) but does not utilize chromatographic techniques to identify the proportions of the various components present at each time point. We have previously established that a very pure hydrophilic porphyrin, porphyrin C (21), exhibits rapid uptake kinetics into the C6 tumor. Maximal porphyrin C levels were observed 45 min and 6 hr after i.v. and i.p. administration, respectively, with subsequent rapid clearance from the tumor (21). Conversely, BOPP, which is far more hydrophobic than porphyrin C, exhibits much slower uptake and longer retention times in the tumor and in this respect is similar to the hydrophobic components of HpD. The kinetics of uptake and clearance of BOPP from blood are also similar to those of HpD. Thus, the BOPP compound appears to combine the best kinetic aspects of the various fractions ofHpD. The high tumor/normal brain ratios and low blood levels suggest that the hydrophobic BOPP molecule probably partitions into lipid-rich membranes within the tumor and is not present in more aqueous environments such as the tumor stroma or blood vessels. This is in contrast to HpD, which has been proposed to localize in the tumor vasculature and have its major site of phototoxic action at those sites (3). The tumor/normal brain ratios are much greater than those obtained with similar doses of HpD in an identical animal model or after a dose of 5 mg per kg of body weight in human glioma patients, where maximal ratios of 50:1 were noted (4) . The data in Figs. 2 and 3 and Table 1 also show that while maximal BOPP uptake in tumor was observed 24 hr after administration, the optimum tumor/ normal brain ratios were observed at 48 hr. This indicates that BOPP is not only selectively taken up by the tumor relative to normal brain, but it is also preferentially retained in tumor. The CLSM micrographs in Fig. 4 provide unequivocal evidence that this sensitizer localizes in the nests of glioma cells invading into the edematous brain adjacent to tumor region, which are thought responsible for tumor recurrence (7) . The subcellular localization in these tumor cells in vivo is similar to the in vitro situation. The exclusion of porphyrins from the nucleus has been reported previously (22, 23) , and while some studies have suggested that porphyrins are taken up by lysosomes (22) , the data presented here and by others (23, 24) show that hydrophobic porphyrins are specifically localized in mitochondria. While PDT has been shown to be a promising adjuvant therapy for cerebral glioma (5) (6) (7) (8) (9) 21) , it is apparent that a factor limiting to its efficacy is the poor penetration of light required to activate the sensitizer in these nests of tumor cells. The greater penetration of a neutron beam may enable activation of the sensitizer, resulting in necrosis of these cells and better local control of the tumor.
While it is not clear whether BOPP has as much phototoxic potential as HpD or whether it induces transient skin photosensitization in the same manner as HpD, the degree and selectivity of uptake suggest that BOPP may be useful as a dual-mode sensitizer for combination PDT and BNCT as adjuvants to conventional surgery in the control of intractable tumors such as glioblastoma multiforme.
